FDA clears Hovilpri for refractory HSV in immunocompromised adults
The FDA approved Hovilpri on October 9, 2026, for immunocompromised adults with HSV lesions that resist standard antivirals, whether or not resistance is confirmed. The decision follows Asahi Kasei’s $920 million acquisition of AiCuris.